HysensBio
Peptide-based therapeutics for regenerative dental treatments.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
* | KRW11.3b Valuation: KRW100.0b | Late VC | |
| Total Funding | 000k | ||
HysensBio is a clinical-stage biotechnology company developing novel treatments for dental conditions based on a cell activation platform. Founded in 2016 by CEO Joo-Cheol Park, the company leverages over two decades of fundamental dental research to create therapies that regenerate physiologic dentin. This core technology addresses unmet needs in the dental market, specifically targeting conditions like dentin hypersensitivity and dental caries (cavities).
The company's primary innovation is based on the discovery that the CPNE7 protein and its derivative functional peptides can induce dentin formation. This has led to the development of a pipeline of drug candidates, including KH-001 for dentin hypersensitivity, which has completed Phase 2 clinical trials in Korea and is ongoing in the USA as of 2024. Another candidate, HBO-001, received Orphan Drug Designation from the U.S. FDA for the treatment of Amelogenesis Imperfecta. The company also has a veterinary dental medicine in its pipeline, HB-901, under an evaluation agreement with Merck Animal Health.
HysensBio operates on a biotechnology business model, focusing on research and development and seeking regulatory approval for its products. Its monetization strategy involves out-licensing and forming joint ventures, such as the one established with Orion Holdings in 2022 to form Orion Biologics. The company has successfully raised significant capital through multiple funding rounds, including Series A, B, and C, to finance its clinical trials and R&D activities. HysensBio has received numerous awards, including the IR52 Jang Young-shil Award from the Ministry of Science & ICT in 2022.
Keywords: regenerative dentistry, dentin regeneration, peptide therapeutics, cell activation, dental caries treatment, dentin hypersensitivity, CPNE7 protein, clinical-stage biotechnology, Amelogenesis Imperfecta, oral biologics, KH-001, veterinary dental medicine, Orion Biologics, Joo-Cheol Park, dental healthcare, tooth regeneration, biopharmaceutical, odontoblast reactivation, dental drug discovery, periodontal ligament.